The Role Of T Helper Cytokines In Indeterminate Colitis
The Role Of T Helper Cytokines In Indeterminate Colitis
DOI:
https://doi.org/10.70284/njirm.v2i1.1887Keywords:
Cytokines, inflammatory bowel diseases, Indeterminate colitisAbstract
Background: Indeterminate colitis is one of the inflammatory bowel diseases that cannot be classified over time as having ulcerative colitis or Crohn’s disease. Dysregulated immunity has been implicated in indeterminate colitis.Aim: to measure serum levels of pro-inflammatory cytokines (tumor necrosis factor (TNF-α), interferon-gamma (IFN-γ) and IL-6 and anti-inflammatory cytokines IL-10 in indeterminate colitis patients. Methods: A cross- sectional study carried out in Al-Kindi Teaching Hospital, Baghdad city from 2007 - 2010. Sixty patients with indeterminate colitis participated in the study. Serum levels of cytokines (IL-6, IL-10, TNF-alpha and IFN-gamma were done by Enzyme Linked Immuno Sorbent Assay (ELISA) and compared with age and sex matched thirty healthy controls. Results: There is a significant increased in IL-10 (p=0.003) and IFN-gamma (p=0.0001) in indeterminate colitis patients. TNF-alpha was significantly decreased (p=0.0001) while IL-6 showed no significance different with control group(p=0.735).Conclusions: There is increase in IL-10 and INF-gamma levels and decrease in TNF-alfa levels in patients with IC.
References
2. Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003; 16:347–358.
3. Burakoff R. Indeterminate Colitis, Clinical Spectrum of Disease. J Clin Gastroenterol.2004; 38; 41-3.
4. Geboes K and Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of pathologist. J Clin Patho.2009:62:201-5.
5. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603.
6. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today. 1993;14:270–274.
7. Elliott DE, Urban JJ, Argo CK, et al. Does the failure to acquire helminthic parasites predispose to Crohn’s disease? FASEB J. 2000;14:1848- 1
8. Smith KM, Eaton AD, Finlayson LM, et al. Oral tolerance. Am J Respir Crit Care Med. 2000;162(suppl):175–178.
9. Laroux FS, Pavlik KP, Wolf RE, et al. Dysregulation of intestinal mucosal immunity: implications in infl ammatory bowel disease. News Physiol Sci. 2001;16:272–277.
10. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-defi cient mice develop chronic enterocolitis. Cell. 1993;75:263–274.
11. Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51:37–43.
12. Yamamoto M, Yoshozaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164:4878–4882.
13. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signalling suppressor T cell
resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med. 2000;6:583–588.
14. Lukacs NW, Chensue SW, Strieter RM, et al. Infl ammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J Immunol. 1994;152:5883–5889.
15. Ardizzone S, Bianchi Porro G. Infl ammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med. 2002;252:475–496.
16. Owczarek D, Cibor D, Szczepanek M, Mach T. Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn. 2009 ;119:84-8.
